Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 66

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 66
---
 the portrayal
of our financial condition and results of operations and require our subjective or complex judgments, resulting in the need to make estimates
about the effect of matters that are inherently uncertain. If actual performance should differ from historical experience or if the underlying
assumptions were to change, our financial condition and results of operations may be materially impacted.

Our
critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition
and Results of Operations—Critical Accounting Policies” in our 2024 Annual Report on Form 10-K. During the six months ended
June 30, 2025, there were no material changes to our critical accounting policies from those discussed in our 2024 Annual Report on Form
10-K.

Recently
Issued Accounting Pronouncements

Certain recently issued accounting pronouncements are discussed in Note 2 to our unaudited condensed consolidated financial statements
included in this Quarterly Report.

Item
3. Quantitative and Qualitative Disclosures about Market Risk

We
are a smaller reporting company as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
and are not required to provide the information otherwise required under this Item 3.

Item
4. Controls and Procedures

Limitations
on Effectiveness of Controls and Procedures

In
designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design
of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply
judgment in evaluating the benefits of possible controls and procedures relative to their costs.

8

Evaluation
of Disclosure Controls and Procedures

Our
management, with the participation of our principal executive officer and principal financial officer, evaluated, as of June 30, 2025,
the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based
on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures
were effective at the reasonable assurance level as of June 30, 2025.

Changes
in Internal Control over Financial Reporting

There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the